<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34816454</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.</ArticleTitle><Pagination><StartPage>180</StartPage><EndPage>186</EndPage><MedlinePgn>180-186</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27467</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Phase 3 study MCI186-19 demonstrated less loss of physical function with edaravone versus placebo, as measured by the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score. A 1-point drop in an individual ALSFRS-R item may be clinically meaningful. We assessed ALSFRS-R item score changes to identify clinical features protected by edaravone treatment.</AbstractText><AbstractText Label="METHODS">Time-to-event analysis was used to assess the cumulative probabilities of reductions in ALSFRS-R item scores and Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) subdomain scores.</AbstractText><AbstractText Label="RESULTS">Edaravone use was accompanied by: (1) delayed drop of &#x2265;1 point in ALSFRS-R item score for four items: salivation, walking, climbing stairs, orthopnea (unadjusted), or for two items: walking, climbing stairs (after Bonferroni correction for multiple comparisons); (2) delayed score transition from 4 or 3 at baseline to &#x2264;2 for five items: swallowing, eating motion, walking, climbing stairs, orthopnea (unadjusted), or for one item: climbing stairs (after Bonferroni correction for multiple comparisons); and (3) delayed worsening of ALSAQ-40 domain scores representing daily living/independence, eating and drinking (unadjusted).</AbstractText><AbstractText Label="DISCUSSION">These post-hoc analyses identified the ALSFRS-R item scores and ALSAQ-40 domain scores that were associated with preserved gross motor function and health-related quality of life, respectively, after edaravone treatment. Limitations of post-hoc analyses should be considered when interpreting these results. We recommend that clinical trials employing the ALSFRS-R include this type of analysis as a pre-specified secondary outcome measure.</AbstractText><CopyrightInformation>&#xa9; 2021 Mitsubishi Tanabe Pharma America, Inc. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Benjamin Rix</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-1914-5061</Identifier><AffiliationInfo><Affiliation>Atrium Health Neurosciences Institute, Carolinas Medical Center, University of North Carolina School of Medicine - Charlotte Campus, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pioro</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials><Identifier Source="ORCID">0000-0002-0737-6065</Identifier><AffiliationInfo><Affiliation>Neuromuscular Division, Davee Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Forbes Norris MDA/ALS Center, California Pacific Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Fumihiro</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takei</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Princeton Pharmatech, Princeton, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apple</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3051-3953</Identifier><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma America, Inc, Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R item scores</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">disease progression</Keyword><Keyword MajorTopicYN="N">functional decline</Keyword><Keyword MajorTopicYN="N">gross motor function</Keyword></KeywordList><CoiStatement>BRB, EPP, and JK are consultants for MTPA. FT and KT are employees of MTPC. JZ is under contract with MTPA. SA is an employee of MTPA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34816454</ArticleId><ArticleId IdType="pmc">PMC9299623</ArticleId><ArticleId IdType="doi">10.1002/mus.27467</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rutkove SB. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):384&#x2010;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404434</ArticleId><ArticleId IdType="pubmed">25582382</ArticleId></ArticleIdList></Reference><Reference><Citation>Stipancic KL, Yunusova Y, Berry JD, Green JR. Minimally detectable change and minimal clinically important difference of a decline in sentence intelligibility and speaking rate for individuals with amyotrophic lateral sclerosis. J Speech Lang Hear Res. 2018;61(11):2757&#x2010;2771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693567</ArticleId><ArticleId IdType="pubmed">30383220</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI&#x2010;186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16(7):505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Post&#x2010;hoc analysis of randomised, placebo&#x2010;controlled, double&#x2010;blind study (MCI186&#x2010;19) of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):49&#x2010;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872913</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone ALS 19 Study Group . Open&#x2010;label 24&#x2010;week extension study of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):55&#x2010;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872920</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial. Neurotherapeutics. 2017;14(3):762&#x2010;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Andrews JA, Genge A, et al. A phase 2, double&#x2010;blind, randomized, dose&#x2010;ranging trial of reldesemtiv in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3&#x2013;4):287&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117790</ArticleId><ArticleId IdType="pubmed">32969758</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, de Jongh AD, Nikolakopoulos S, et al. An old friend who has overstayed their welcome: the ALSFRS&#x2010;R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3&#x2010;4):300&#x2010;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">33527843</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>